Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at diagnosis \<18 years and \>=6 years~* New diagnosis of CD based on Porto criteria~* CD with inflammatory phenotype (non-penetrating, non-fistulizing) and with no need for surgery except for perinal fistulas~* Presence of at least one of the following risk factors for poor prognosis:~  * fistulizing perianal disease~ * pan-enteric disease~ * disease extension \> 60 cm~ * severe growth delay (height z-score \< -2 DS)~ * severe osteoporosis (z score \< -2 DS)~ * hypoalbuminemia (\< 3g/dL) or high C-reactive protein (2 times higher the normal range)~* Acceptance of the Risk Evaluation and Mitigation Strategy (REMS) program for reducing the teratogenic risk.~Exclusion Criteria:~* ongoing pregnancy~* presence of peripheral neuropathy~* HIV~* patients with transplanted organs~* ongoing major infections or other severe diseases~* participation to other experimental studies.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Thalidomide (Type: EXPERIMENTAL): Thalidomide is a immunomodulatory and antiangiogenetic drug with anti tumor necrosis factor (TNF) alpha properties
- Infliximab (Type: ACTIVE_COMPARATOR): Infliximab is a chimeric monoclonal antibody against TNF alpha

Based on this trial design, predict the completion outcome and termination type (if applicable).